CHRN

ChronoScale Holdings Corporation Common Stock

CHRN
Closed
$16.91
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
Country

US

CEO

Mr. Scott Davis

IPO date

2013

Employees

50

ISIN

US2826444000

Key stats

Open

$17.89

Volume

670.37K

Market cap

$2.39B

Prev. close

$16.48

Impl / hst vl

-

Open interest

$0.00

$15.74

Day’s Range

$18.34

$12.55

52W Range

$28.20

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
-
P/B
-
Current ratio
1.55
Debt / Equity
-0.03
ROE
-177.40%
Gross margin
50.16%
Income growth
55.35%
FCF growth
-52.37

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$9.69
The top 3 analysts forecasts that 12-month price may decrease by 42.70%, with a low of $9.60 and a high of $9.98
$9.60
Low
$9.69
Avg
$9.98
High
Current price

Earnings

Q1 ‘26 revenue
$2.14M
Q1 ‘26 net income
-$7.26M
Revenue
Net income
Previous EPS
-$2.04
Estimate EPS
-$0.06
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply